BROSSARD, Quebec, Sept. 25, 2019 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the appointment of Mr. François Côté as Chairman of the Corporation’s board of directors (the “Board”), effective today, in replacement of Mr. Georges Hébert who will remain a member of the Board. The Corporation also announces stock option grants to its directors and officers.
“I am pleased that François has accepted the role of Chairman of the Board. His great knowledge of the healthcare industry and his business relationships will continue benefitting DIAGNOS. As I remain a director of the Corporation, François can count on my support and the support of my fellow directors”, said Mr. Georges Hébert, outgoing chairman of the Board. The appointment of Mr. Côté to the Board was initially announced on June 18, 2019.
The Board has approved a grant totalling 2,250,000 stock options to its directors and officers. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The exercise price of these options has been established at $0.20 per share. The expiry date to which these options can be exercised has been fixed to September 25, 2024.
The Corporation also announces that it has received final acceptance from the TSX Venture for (i) the amendment to its stock option plan (the “Plan”) pursuant to which the maximum number of common shares of the Corporation that may be issued under the Plan be set at 6,000,000, as detailed in the September 20, 2019 announcement on the voting results of the annual and special meeting of shareholders, and (ii) a private placement for gross receipts of $550,000, as detailed in the September 16, 2019 announcement on the closing of the private placement.
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.
Additional information is available at www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc
Tel: 450-678-8882 ext. 224
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
